Preventive effects of chebulic acid isolated from Terminalia chebula on advanced glycation endproduct-induced endothelial cell dysfunction

Journal of Ethnopharmacology

Volumn 131, Issue 3, 2010, Pages 567-574

  Lee, Hyun Sun ^a   Koo, Yoon Chang ^a   Suh, Hyung Joo ^a   Kim, Kyung Yong ^b   Lee, Kwang Won ^a  

^a Korea University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Advanced glycation endproducts; Chebulic acid; Diabetic complications; Endothelial dysfunction; Terminaila chebula

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CHEBULIC ACID; REACTIVE OXYGEN METABOLITE; TERMINALIA CHEBULA EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRIC RESISTANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FRUIT; HUMAN; HUMAN CELL; LEUKOCYTE ADHERENCE; MONOCYTE; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; TERMINALIA CHEBULA;

CELL ADHESION; CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FRUIT; GLYCERALDEHYDE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROLYZABLE TANNINS; MONOCYTES; REACTIVE OXYGEN SPECIES; TERMINALIA; UMBILICAL VEINS;

TERMINALIA; TERMINALIA CHEBULA;

EID: 77956647697     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.07.039     Document Type: Article

References (41)

1. Badmaev V., Nowakowski M. Protection of epithelial cells against influenza A virus by a plant derived biological response modifier Ledretan-96. Phytotherapy Research 2000, 14:245-249.
2. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
3. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annual Review of Medicine 1995, 46:223-234.
4. Calcutt N.A., Cooper M.E., Kern T.S., Schmidt A.M. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 2009, 8:417-429.
5. Choi S.Y., Jung S.H., Lee H.S., Park K.W., Yun B.S., Lee K.W. Glycation inhibitory activity and the identification of an active compound in Plantago asiatica extract. Phytotherapy Research 2008, 22:323-329.
6. Cohen J.D. Overview of physiology, vascular biology, and mechanisms of hypertension. Journal of Managed Care Pharmacy 2007, 13:S6-S8.
7. Hiraoka M, Nitta N., Nagai M., Shimokado K., Yoshida M. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Science 2004, 75:1333-1341.
8. Huijberts M.S., Wolffenbuttel B.H., Boudier H.A., Crijns F.R., Kruseman A.C., Poitevin P., Levy B.I. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. Journal of Clinical Investigation 1993, 92:1407-1411.
9. Jay D., Hitomi H., Griendling K.K. Oxidative stress and diabetic cardiovascular complications. Free Radical Biology and Medicine 2006, 40:183-192.
10. Juang L.J., Sheu S.J., Lin T.C. Determination of hydrolyzable tannins in the fruit of Terminalia chebula Retz. by high-performance liquid chromatography and capillary electrophoresis. Journal of Separation Science 2004, 27:718-724.
11. Kazakoff P.W., McGuire T.R., Hoie E.B., Cano M., Iversen P.L. An in vitro model for endothelial permeability: assessment of monolayer integrity. In Vitro Cellular and Developmental Biology: Animal 1995, 31:846-852.
12. Laakso M., Kuusisto J. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Annals of Medicine 1996, 28:415-418.
13. Lee H.S., Jung S.H., Yun B.S., Lee K.W. Isolation of chebulic acid from Terminalia chebula Retz. and its antioxidant effect in isolated rat hepatocytes. Archives of Toxicology 2007, 81:211-218.
14. Lee K.-W., Mossine V., Ortwerth B.J. The relative ability of glucose and ascorbate to glycate and crosslink lens proteins in vitro. Experimental Eye Research 1998, 67:95-104.
15. Lehman T.D., Ortwerth B.J. Inhibitors of advanced glycation end product-associated protein cross-linking. Biochimica et Biophysica Acta (BBA): Molecular Basis of Disease 2001, 1535:110-119.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983, 65:55-63.
17. Murali Y.K., Anand P., Tandon V., Singh R., Chandra R., Murthy P.S. Long-term effects of Terminalia chebula Retz. on hyperglycemia and associated hyperlipidemia, tissue glycogen content and in vitro release of insulin in streptozotocin induced diabetic rats. Experimental Clinical Endocrinology & Diabetes 2007, 115:641-646.
18. Naik G.H., Priyadarsini K.I., Bhagirathi R.G., Mishra B., Mishra K.P., Banavalikar M.M., Mohan H. In vitro antioxidant studies and free radical reactions of triphala, an ayurvedic formulation and its constituents. Phytotherapy Research 2005, 19:582-586.
19. Ohashi S., Abe H., Takahashi T., Yamamoto Y., Takeuchi M., Arai H., Nagata K., Kita T., Okamoto H., Yamamoto H., Doi T. Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy. Journal of Biological Chemistry 2004, 279:19816-19823.
20. Rao N.K., Nammi S. Antidiabetic and renoprotective effects of the chloroform extract of Terminalia chebula Retz. seeds in streptozotocin-induced diabetic rats. BMC Complementary and Alternative Medicine 2006, 6:17-22.
21. Renier G., Mamputu J.C., Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 2003, 52:13-18.
22. Roffey B.W.C., Atwal A.S., Johns T., Kubow S. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. Journal of Ethnopharmacology 2007, 112:77-84.
23. Sabu M.C., Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. Journal of Ethnopharmacology 2002, 81:155-160.
24. Saleem A., Husheem M., Harkonen P., Pihlaja K. Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula Retz. fruit. Journal of Ethnopharmacology 2002, 81:327-336.
25. Saleh H.H., Rashad H., Khafaga S. Pharmacological action of Terminalia chebula. Journal of the Egyptian Medical Association 1952, 35:763-771.
26. Sato Y., Oketani H., Singyouchi K., Ohtsubo T., Kihara M., Shibata H., Higuti T. Extraction and purification of effective antimicrobial constituents of Terminalia chebula Rets. against methicillin-resistant Staphylococcus aureus. Biological and Pharmaceutical Bulletin 1997, 20:401-404.
27. Shaila H.P., Udupa S.L., Udupa A.L. Hypolipidemic activity of three indigenous drugs in experimentally induced atherosclerosis. International Journal of Cardiology 1998, 67:119-124.
28. Shin T.Y., Jeong H.J., Kim D.K., Kim S.H., Lee J.K., Chae B.S., Kim J.H., Kang H.W., Lee C.M., Lee K.C., Park S.T., Lee E.J., Lim J.P., Kim H.M., Lee Y.M. Inhibitory action of water soluble fraction of Terminalia chebula on systemic and local anaphylaxis. Journal of Ethnopharmacology 2001, 74:133-140.
29. Shukla S.K., Chaudhary P., Prem Kumar I., Afrin F., Puri S.C., Qazi G.N., Sharma R.K. Cytotoxic and radioprotective effects of Podophyllum hexandrum. Environmental Toxicology and Pharmacology 2006, 22:113-120.
30. Takeuchi M., Bucala R., Suzuki T., Ohkubo T., Yamazaki M., Koike T., Kameda Y., Makita Z. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. Journal of Neuropathology and Experimental Neurology 2000, 59:1094-1105.
31. Takeuchi M., Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Medical Hypotheses 2004, 63:453-455.
32. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 2005, 353:2643-2653.
33. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Archives of Biochemistry and Biophysics 2003, 419:31-40.
34. Twigg S.M., Cao Z., McLennan S.V., Burns W.C., Brammar G., Forbes J.M., Cooper M.E. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002, 143:4907-4915.
35. Wautier M.-P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.-L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. American Journal of Physiology, Endocrinology and Metabolism 2001, 280:E685-E694.
36. Wendt T., Tanji N., Guo J., Hudson B.I., Bierhaus A., Ramasamy R., Arnold B., Nawroth P.P., Yan S.F., D'Agati V., Schmidt A.M. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. Journal of the American Society of Nephrology 2003, 14:1383-1395.
37. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Journal of the American Medical Association 2003, 290:2159-2167.
38. Xu S.W., Howat S.L., Renzoni E.A., Holmes A., Pearson J.D., Dashwood M.R., Bou-Gharios G., Denton C.P., du Bois R.M., Black C.M., Leask A., Abraham D.J. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. Journal of Biological Chemistry 2004, 279:23098-23103.
39. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., Makita Z. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. Journal of Biological Chemistry 2002, 277:20309-20315.
40. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs 2008, 17:983-996.
41. Zannad F. Implications of the ADVANCE study for clinical practice. Journal of Hypertension 2008, 26(Suppl. 3):S31-S34.